Natalia Nunez-Fernandez

Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: January 16, 2026

Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients.

Journal: Pharmacological research

Published: December 02, 2025

Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia.

Journal: Frontiers in oncology

Published: August 01, 2025

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group.

Journal: BMC cancer

Published: July 29, 2025

Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study.

Journal: Clinical genitourinary cancer

Published: April 24, 2025

Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 06, 2025

Correction: Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 04, 2025

Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non-small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study.

Journal: Cancer treatment and research communications

Published: March 13, 2025

Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 13, 2024

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 19, 2021

Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients.

Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients.

Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia.

Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia.

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group.

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group.

Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study.

Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study.

Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.

Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.

Correction: Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Correction: Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non-small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study.

Assessment of efficacy, safety, and prognostic/predictive factors of nintedanib/docetaxel in advanced/recurrent non-small cell lung cancer post-immunotherapy and chemotherapy: A Galician Lung Cancer Group study.

Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.

Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer.

Thoughts on the shortage of vinflunine: could we have done more?

Thoughts on the shortage of vinflunine: could we have done more?

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.